Repeated Methylglyoxal Treatment Depletes Dopamine in the Prefrontal Cortex, and Causes Memory Impairment and Depressive-Like Behavior in Mice

Methylglyoxal (MGO) is a highly reactive dicarbonyl molecule that promotes the formation of advanced glycation end products (AGEs), which are believed to play a key role in a number of pathologies, such as diabetes, Alzheimer’s disease, and inflammation. Here, Swiss mice were treated with MGO by int...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurochemical research 2020-02, Vol.45 (2), p.354-370
Hauptverfasser: Szczepanik, Jozimar Carlos, de Almeida, Gudrian Ricardo Lopes, Cunha, Mauricio Peña, Dafre, Alcir Luiz
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 370
container_issue 2
container_start_page 354
container_title Neurochemical research
container_volume 45
creator Szczepanik, Jozimar Carlos
de Almeida, Gudrian Ricardo Lopes
Cunha, Mauricio Peña
Dafre, Alcir Luiz
description Methylglyoxal (MGO) is a highly reactive dicarbonyl molecule that promotes the formation of advanced glycation end products (AGEs), which are believed to play a key role in a number of pathologies, such as diabetes, Alzheimer’s disease, and inflammation. Here, Swiss mice were treated with MGO by intraperitoneal injection to investigate its effects on motor activity, mood, and cognition. Acute MGO treatment heavily decreased locomotor activity in the open field test at higher doses (80–200 mg/kg), an effect not observed at lower doses (10–50 mg/kg). Several alterations were observed 4 h after a single MGO injection (10–50 mg/kg): (a) plasma MGO levels were increased, (b) memory was impaired (object location task), (c) anxiolytic behavior was observed in the open field and marble burying test, and (d) depressive-like behavior was evidenced as evaluated by the tail suspension test. Biochemical alterations in the glutathione and glyoxalase systems were not observed 4 h after MGO treatment. Mice were also treated daily with MGO at 0, 10, 25 and 50 mg/kg for 11 days. From the 5th to the 11th day, several behavioral end points were evaluated, resulting in: (a) absence of motor impairment as evaluated in the open field, horizontal bars and pole test, (b) depressive-like behavior observed in the tail suspension test, and (c) cognitive impairments detected on working, short- and long-term memory when mice were tested in the Y-maze spontaneous alternation, object location and recognition tests, and step-down inhibitory avoidance task. An interesting finding was a marked decrease in dopamine levels in the prefrontal cortex of mice treated with 50 mg/kg MGO for 11 days, along with a ~ 25% decrease in the Glo1 content. The MGO-induced dopamine depletion in the prefrontal cortex may be related to the observed memory deficits and depressive-like behavior, an interesting topic to be further studied as a potentially novel route for MGO toxicity.
doi_str_mv 10.1007/s11064-019-02921-2
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2346370935</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2346370935</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-49c2f1e07124fbdd56defdd39c02196a121b56b1cd6e54466f6dfeba250434143</originalsourceid><addsrcrecordid>eNp9kc1u2zAQhIkiReO4fYEeCgK5RimXpKjqmNhpEsBGgsI9C5S4iuVKokLSRvwSfebSP0luPRHgfDOL3SHkK7BLYCz77gGYkgmDPGE855DwD2QEaSYSlTNxQkZMRFlAzk7JmfcrxqKNwydyKiD7oTLIRuTvLxxQBzR0jmG5bZ_arX3RLV24-NthH-gUhxYDejq1g-6aHmnT07BE-uiwdrYPkZ5YF_Dlgure0Ile-0jPsbNuS--7QTduH7QTY5hD75sNJrPmD9JrXOpNY90uc95U-Jl8rHXr8cvxHZPfP28Wk7tk9nB7P7maJZWUEBKZV7wGZBlwWZfGpMpgbYzIq7hfrjRwKFNVQmUUplIqVStTY6l5yqSQIMWYnB9yB2ef1-hDsbJr18eRBRdSiYzlIo0UP1CVs97HdYvBNZ122wJYsaugOFRQxAqKfQXRPSbfjtHrskPzZnm9eQTEAfBR6p_Qvc_-T-w_rd2TBg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2346370935</pqid></control><display><type>article</type><title>Repeated Methylglyoxal Treatment Depletes Dopamine in the Prefrontal Cortex, and Causes Memory Impairment and Depressive-Like Behavior in Mice</title><source>SpringerNature Journals</source><creator>Szczepanik, Jozimar Carlos ; de Almeida, Gudrian Ricardo Lopes ; Cunha, Mauricio Peña ; Dafre, Alcir Luiz</creator><creatorcontrib>Szczepanik, Jozimar Carlos ; de Almeida, Gudrian Ricardo Lopes ; Cunha, Mauricio Peña ; Dafre, Alcir Luiz</creatorcontrib><description>Methylglyoxal (MGO) is a highly reactive dicarbonyl molecule that promotes the formation of advanced glycation end products (AGEs), which are believed to play a key role in a number of pathologies, such as diabetes, Alzheimer’s disease, and inflammation. Here, Swiss mice were treated with MGO by intraperitoneal injection to investigate its effects on motor activity, mood, and cognition. Acute MGO treatment heavily decreased locomotor activity in the open field test at higher doses (80–200 mg/kg), an effect not observed at lower doses (10–50 mg/kg). Several alterations were observed 4 h after a single MGO injection (10–50 mg/kg): (a) plasma MGO levels were increased, (b) memory was impaired (object location task), (c) anxiolytic behavior was observed in the open field and marble burying test, and (d) depressive-like behavior was evidenced as evaluated by the tail suspension test. Biochemical alterations in the glutathione and glyoxalase systems were not observed 4 h after MGO treatment. Mice were also treated daily with MGO at 0, 10, 25 and 50 mg/kg for 11 days. From the 5th to the 11th day, several behavioral end points were evaluated, resulting in: (a) absence of motor impairment as evaluated in the open field, horizontal bars and pole test, (b) depressive-like behavior observed in the tail suspension test, and (c) cognitive impairments detected on working, short- and long-term memory when mice were tested in the Y-maze spontaneous alternation, object location and recognition tests, and step-down inhibitory avoidance task. An interesting finding was a marked decrease in dopamine levels in the prefrontal cortex of mice treated with 50 mg/kg MGO for 11 days, along with a ~ 25% decrease in the Glo1 content. The MGO-induced dopamine depletion in the prefrontal cortex may be related to the observed memory deficits and depressive-like behavior, an interesting topic to be further studied as a potentially novel route for MGO toxicity.</description><identifier>ISSN: 0364-3190</identifier><identifier>EISSN: 1573-6903</identifier><identifier>DOI: 10.1007/s11064-019-02921-2</identifier><identifier>PMID: 31786717</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Advanced glycosylation end products ; Alzheimer's disease ; Biochemistry ; Biomedical and Life Sciences ; Biomedicine ; Cell Biology ; Cognition ; Cognitive ability ; Depletion ; Diabetes mellitus ; Dopamine ; Field tests ; Glutathione ; Glycosylation ; Impairment ; Injection ; Locomotor activity ; Long term memory ; Memory ; Mental task performance ; Mood ; Motor activity ; Neurochemistry ; Neurodegenerative diseases ; Neurology ; Neurosciences ; Object recognition ; Open-field behavior ; Original Paper ; Prefrontal cortex ; Pyruvaldehyde ; Spontaneous alternation ; Toxicity</subject><ispartof>Neurochemical research, 2020-02, Vol.45 (2), p.354-370</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2019</rights><rights>Neurochemical Research is a copyright of Springer, (2019). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-49c2f1e07124fbdd56defdd39c02196a121b56b1cd6e54466f6dfeba250434143</citedby><cites>FETCH-LOGICAL-c441t-49c2f1e07124fbdd56defdd39c02196a121b56b1cd6e54466f6dfeba250434143</cites><orcidid>0000-0003-0997-8622 ; 0000-0002-0371-7002 ; 0000-0002-0269-7521 ; 0000-0001-8097-4611</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11064-019-02921-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11064-019-02921-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31786717$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Szczepanik, Jozimar Carlos</creatorcontrib><creatorcontrib>de Almeida, Gudrian Ricardo Lopes</creatorcontrib><creatorcontrib>Cunha, Mauricio Peña</creatorcontrib><creatorcontrib>Dafre, Alcir Luiz</creatorcontrib><title>Repeated Methylglyoxal Treatment Depletes Dopamine in the Prefrontal Cortex, and Causes Memory Impairment and Depressive-Like Behavior in Mice</title><title>Neurochemical research</title><addtitle>Neurochem Res</addtitle><addtitle>Neurochem Res</addtitle><description>Methylglyoxal (MGO) is a highly reactive dicarbonyl molecule that promotes the formation of advanced glycation end products (AGEs), which are believed to play a key role in a number of pathologies, such as diabetes, Alzheimer’s disease, and inflammation. Here, Swiss mice were treated with MGO by intraperitoneal injection to investigate its effects on motor activity, mood, and cognition. Acute MGO treatment heavily decreased locomotor activity in the open field test at higher doses (80–200 mg/kg), an effect not observed at lower doses (10–50 mg/kg). Several alterations were observed 4 h after a single MGO injection (10–50 mg/kg): (a) plasma MGO levels were increased, (b) memory was impaired (object location task), (c) anxiolytic behavior was observed in the open field and marble burying test, and (d) depressive-like behavior was evidenced as evaluated by the tail suspension test. Biochemical alterations in the glutathione and glyoxalase systems were not observed 4 h after MGO treatment. Mice were also treated daily with MGO at 0, 10, 25 and 50 mg/kg for 11 days. From the 5th to the 11th day, several behavioral end points were evaluated, resulting in: (a) absence of motor impairment as evaluated in the open field, horizontal bars and pole test, (b) depressive-like behavior observed in the tail suspension test, and (c) cognitive impairments detected on working, short- and long-term memory when mice were tested in the Y-maze spontaneous alternation, object location and recognition tests, and step-down inhibitory avoidance task. An interesting finding was a marked decrease in dopamine levels in the prefrontal cortex of mice treated with 50 mg/kg MGO for 11 days, along with a ~ 25% decrease in the Glo1 content. The MGO-induced dopamine depletion in the prefrontal cortex may be related to the observed memory deficits and depressive-like behavior, an interesting topic to be further studied as a potentially novel route for MGO toxicity.</description><subject>Advanced glycosylation end products</subject><subject>Alzheimer's disease</subject><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cell Biology</subject><subject>Cognition</subject><subject>Cognitive ability</subject><subject>Depletion</subject><subject>Diabetes mellitus</subject><subject>Dopamine</subject><subject>Field tests</subject><subject>Glutathione</subject><subject>Glycosylation</subject><subject>Impairment</subject><subject>Injection</subject><subject>Locomotor activity</subject><subject>Long term memory</subject><subject>Memory</subject><subject>Mental task performance</subject><subject>Mood</subject><subject>Motor activity</subject><subject>Neurochemistry</subject><subject>Neurodegenerative diseases</subject><subject>Neurology</subject><subject>Neurosciences</subject><subject>Object recognition</subject><subject>Open-field behavior</subject><subject>Original Paper</subject><subject>Prefrontal cortex</subject><subject>Pyruvaldehyde</subject><subject>Spontaneous alternation</subject><subject>Toxicity</subject><issn>0364-3190</issn><issn>1573-6903</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kc1u2zAQhIkiReO4fYEeCgK5RimXpKjqmNhpEsBGgsI9C5S4iuVKokLSRvwSfebSP0luPRHgfDOL3SHkK7BLYCz77gGYkgmDPGE855DwD2QEaSYSlTNxQkZMRFlAzk7JmfcrxqKNwydyKiD7oTLIRuTvLxxQBzR0jmG5bZ_arX3RLV24-NthH-gUhxYDejq1g-6aHmnT07BE-uiwdrYPkZ5YF_Dlgure0Ile-0jPsbNuS--7QTduH7QTY5hD75sNJrPmD9JrXOpNY90uc95U-Jl8rHXr8cvxHZPfP28Wk7tk9nB7P7maJZWUEBKZV7wGZBlwWZfGpMpgbYzIq7hfrjRwKFNVQmUUplIqVStTY6l5yqSQIMWYnB9yB2ef1-hDsbJr18eRBRdSiYzlIo0UP1CVs97HdYvBNZ122wJYsaugOFRQxAqKfQXRPSbfjtHrskPzZnm9eQTEAfBR6p_Qvc_-T-w_rd2TBg</recordid><startdate>20200201</startdate><enddate>20200201</enddate><creator>Szczepanik, Jozimar Carlos</creator><creator>de Almeida, Gudrian Ricardo Lopes</creator><creator>Cunha, Mauricio Peña</creator><creator>Dafre, Alcir Luiz</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QR</scope><scope>7TK</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><orcidid>https://orcid.org/0000-0003-0997-8622</orcidid><orcidid>https://orcid.org/0000-0002-0371-7002</orcidid><orcidid>https://orcid.org/0000-0002-0269-7521</orcidid><orcidid>https://orcid.org/0000-0001-8097-4611</orcidid></search><sort><creationdate>20200201</creationdate><title>Repeated Methylglyoxal Treatment Depletes Dopamine in the Prefrontal Cortex, and Causes Memory Impairment and Depressive-Like Behavior in Mice</title><author>Szczepanik, Jozimar Carlos ; de Almeida, Gudrian Ricardo Lopes ; Cunha, Mauricio Peña ; Dafre, Alcir Luiz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-49c2f1e07124fbdd56defdd39c02196a121b56b1cd6e54466f6dfeba250434143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Advanced glycosylation end products</topic><topic>Alzheimer's disease</topic><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cell Biology</topic><topic>Cognition</topic><topic>Cognitive ability</topic><topic>Depletion</topic><topic>Diabetes mellitus</topic><topic>Dopamine</topic><topic>Field tests</topic><topic>Glutathione</topic><topic>Glycosylation</topic><topic>Impairment</topic><topic>Injection</topic><topic>Locomotor activity</topic><topic>Long term memory</topic><topic>Memory</topic><topic>Mental task performance</topic><topic>Mood</topic><topic>Motor activity</topic><topic>Neurochemistry</topic><topic>Neurodegenerative diseases</topic><topic>Neurology</topic><topic>Neurosciences</topic><topic>Object recognition</topic><topic>Open-field behavior</topic><topic>Original Paper</topic><topic>Prefrontal cortex</topic><topic>Pyruvaldehyde</topic><topic>Spontaneous alternation</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Szczepanik, Jozimar Carlos</creatorcontrib><creatorcontrib>de Almeida, Gudrian Ricardo Lopes</creatorcontrib><creatorcontrib>Cunha, Mauricio Peña</creatorcontrib><creatorcontrib>Dafre, Alcir Luiz</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Neurochemical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Szczepanik, Jozimar Carlos</au><au>de Almeida, Gudrian Ricardo Lopes</au><au>Cunha, Mauricio Peña</au><au>Dafre, Alcir Luiz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Repeated Methylglyoxal Treatment Depletes Dopamine in the Prefrontal Cortex, and Causes Memory Impairment and Depressive-Like Behavior in Mice</atitle><jtitle>Neurochemical research</jtitle><stitle>Neurochem Res</stitle><addtitle>Neurochem Res</addtitle><date>2020-02-01</date><risdate>2020</risdate><volume>45</volume><issue>2</issue><spage>354</spage><epage>370</epage><pages>354-370</pages><issn>0364-3190</issn><eissn>1573-6903</eissn><abstract>Methylglyoxal (MGO) is a highly reactive dicarbonyl molecule that promotes the formation of advanced glycation end products (AGEs), which are believed to play a key role in a number of pathologies, such as diabetes, Alzheimer’s disease, and inflammation. Here, Swiss mice were treated with MGO by intraperitoneal injection to investigate its effects on motor activity, mood, and cognition. Acute MGO treatment heavily decreased locomotor activity in the open field test at higher doses (80–200 mg/kg), an effect not observed at lower doses (10–50 mg/kg). Several alterations were observed 4 h after a single MGO injection (10–50 mg/kg): (a) plasma MGO levels were increased, (b) memory was impaired (object location task), (c) anxiolytic behavior was observed in the open field and marble burying test, and (d) depressive-like behavior was evidenced as evaluated by the tail suspension test. Biochemical alterations in the glutathione and glyoxalase systems were not observed 4 h after MGO treatment. Mice were also treated daily with MGO at 0, 10, 25 and 50 mg/kg for 11 days. From the 5th to the 11th day, several behavioral end points were evaluated, resulting in: (a) absence of motor impairment as evaluated in the open field, horizontal bars and pole test, (b) depressive-like behavior observed in the tail suspension test, and (c) cognitive impairments detected on working, short- and long-term memory when mice were tested in the Y-maze spontaneous alternation, object location and recognition tests, and step-down inhibitory avoidance task. An interesting finding was a marked decrease in dopamine levels in the prefrontal cortex of mice treated with 50 mg/kg MGO for 11 days, along with a ~ 25% decrease in the Glo1 content. The MGO-induced dopamine depletion in the prefrontal cortex may be related to the observed memory deficits and depressive-like behavior, an interesting topic to be further studied as a potentially novel route for MGO toxicity.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>31786717</pmid><doi>10.1007/s11064-019-02921-2</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0003-0997-8622</orcidid><orcidid>https://orcid.org/0000-0002-0371-7002</orcidid><orcidid>https://orcid.org/0000-0002-0269-7521</orcidid><orcidid>https://orcid.org/0000-0001-8097-4611</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0364-3190
ispartof Neurochemical research, 2020-02, Vol.45 (2), p.354-370
issn 0364-3190
1573-6903
language eng
recordid cdi_proquest_journals_2346370935
source SpringerNature Journals
subjects Advanced glycosylation end products
Alzheimer's disease
Biochemistry
Biomedical and Life Sciences
Biomedicine
Cell Biology
Cognition
Cognitive ability
Depletion
Diabetes mellitus
Dopamine
Field tests
Glutathione
Glycosylation
Impairment
Injection
Locomotor activity
Long term memory
Memory
Mental task performance
Mood
Motor activity
Neurochemistry
Neurodegenerative diseases
Neurology
Neurosciences
Object recognition
Open-field behavior
Original Paper
Prefrontal cortex
Pyruvaldehyde
Spontaneous alternation
Toxicity
title Repeated Methylglyoxal Treatment Depletes Dopamine in the Prefrontal Cortex, and Causes Memory Impairment and Depressive-Like Behavior in Mice
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T14%3A01%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Repeated%20Methylglyoxal%20Treatment%20Depletes%20Dopamine%20in%20the%20Prefrontal%20Cortex,%20and%20Causes%20Memory%20Impairment%20and%20Depressive-Like%20Behavior%20in%20Mice&rft.jtitle=Neurochemical%20research&rft.au=Szczepanik,%20Jozimar%20Carlos&rft.date=2020-02-01&rft.volume=45&rft.issue=2&rft.spage=354&rft.epage=370&rft.pages=354-370&rft.issn=0364-3190&rft.eissn=1573-6903&rft_id=info:doi/10.1007/s11064-019-02921-2&rft_dat=%3Cproquest_cross%3E2346370935%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2346370935&rft_id=info:pmid/31786717&rfr_iscdi=true